Skip to main content
. 2016 Apr 21;7(24):36311–36320. doi: 10.18632/oncotarget.8904

Table 2. Summary of EGFR TKI treatment outcome.

Characteristic N %
Number of previous treatment
0 101 74.3
1 32 23.5
2 3 2.2
Best response
 Complete response 0 0
 Partial response 87 63.8
 Stable disease 33 24.5
 Progressive disease 6 4.4
 Not assessable 10 7.3
EGFR TKI
 Gefitinib 136 100
 Erlotinib 0 0